166 related articles for article (PubMed ID: 28789820)
1. Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia.
Butler K; Day C; Sutherland R; van Buskirk J; Breen C; Burns L; Larney S
Int J Drug Policy; 2017 Sep; 47():102-106. PubMed ID: 28789820
[TBL] [Abstract][Full Text] [Related]
2. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.
Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L
Int J Drug Policy; 2017 Sep; 47():77-85. PubMed ID: 28578863
[TBL] [Abstract][Full Text] [Related]
3. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
[TBL] [Abstract][Full Text] [Related]
4. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.
Iversen J; Wand H; McManus H; Dore GJ; Maher L
Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842
[TBL] [Abstract][Full Text] [Related]
5. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
[TBL] [Abstract][Full Text] [Related]
7. Engaging people who inject drugs in hepatitis C virus testing and prevention through community-based outreach, in Sydney, Australia.
Coupland H; White B; Bates A; Park JN; Iversen J; Maher L
Drug Alcohol Rev; 2019 Feb; 38(2):177-184. PubMed ID: 30652363
[TBL] [Abstract][Full Text] [Related]
8. Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014.
Blackburn NA; Patel RC; Zibbell JE
Public Health Rep; 2016; 131 Suppl 2(Suppl 2):91-7. PubMed ID: 27168667
[TBL] [Abstract][Full Text] [Related]
9. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
[TBL] [Abstract][Full Text] [Related]
10. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.
Solomon SS; Mehta SH; Srikrishnan AK; Solomon S; McFall AM; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Lucas GM; Kumar MS; Sulkowski MS; Quinn TC
Lancet Infect Dis; 2015 Jan; 15(1):36-45. PubMed ID: 25486851
[TBL] [Abstract][Full Text] [Related]
11. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study.
Marshall AD; Micallef M; Erratt A; Telenta J; Treloar C; Everingham H; Jones SC; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop A; Jauncey M; Read P; Collie T; Dore GJ; Grebely J
Int J Drug Policy; 2015 Oct; 26(10):984-91. PubMed ID: 26256938
[TBL] [Abstract][Full Text] [Related]
12. Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
Williams B; Howell J; Doyle J; Thompson AJ; Draper B; Layton C; Latham N; Bramwell F; Membrey D; Mcpherson M; Roney J; Stoové M; Hellard ME; Pedrana A
Int J Drug Policy; 2019 Oct; 72():91-98. PubMed ID: 31129023
[TBL] [Abstract][Full Text] [Related]
13. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J;
Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881
[TBL] [Abstract][Full Text] [Related]
14. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
15. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system.
Butler K; Larney S; Day CA; Burns L
Drug Alcohol Rev; 2019 Mar; 38(3):264-269. PubMed ID: 30548702
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
Kåberg M; Hammarberg A; Lidman C; Weiland O
Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
[TBL] [Abstract][Full Text] [Related]
17. The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia: Major gaps for migrants.
Folch C; Saludes V; Reyes-Ureña J; Antuori A; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
Int J Drug Policy; 2021 Apr; 90():103057. PubMed ID: 33310634
[TBL] [Abstract][Full Text] [Related]
18. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.
Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L
J Viral Hepat; 2014 Mar; 21(3):198-207. PubMed ID: 24438681
[TBL] [Abstract][Full Text] [Related]
19. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia.
Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159
[TBL] [Abstract][Full Text] [Related]
20. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection.
Artenie AA; Zang G; Daniel M; Fortier E; Jutras-Aswad D; Puzhko S; Bruneau J
Int J Drug Policy; 2017 Sep; 47():239-243. PubMed ID: 28587944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]